OrbiMed-backed Audentes Therapeutics prices IPO at $15, within the range

Audentes Therapeutics, a preclinical biotech developing gene therapies for rare diseases, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Audentes Therapeutics plans to list on the Nasdaq under the symbol BOLD. BofA Merrill Lynch, Cowen & Company, and Piper Jaffray acted as lead managers on the deal.

Read More : Impinj prices upsized IPO

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.